Trials / Completed
CompletedNCT06503250
A Study of Participants With Initially Unresectable Hepatocellular Carcinoma That is Treated With Atezolizumab and Bevacizumab Plus Transarterial Chemoembolization
Effectiveness and Safety of Atezolizumab and Bevacizumab Plus Transarterial Chemoembolization as Conversion Therapy Among Patients With Initially Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice in China
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 113 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, retrospective, observational cohort study to describe the effectiveness and safety of Atezo+Bev plus Transarterial Chemoembolization (TACE) among adult patients with unresectable hepatocellular carcinoma (HCC) in real-world clinical practice in China. Eligible patients diagnosed with unresectable HCC initiating the Atezo+Bev and TACE between 28 October 2020 and 31 December 2023 will be included in this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Atezolizumab | Observational Study |
| DRUG | Bevacizumab | Observational Study |
| RADIATION | Transarterial Chemoembolization | Observational Study |
Timeline
- Start date
- 2024-07-19
- Primary completion
- 2024-11-27
- Completion
- 2024-11-27
- First posted
- 2024-07-16
- Last updated
- 2025-03-21
Locations
5 sites across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06503250. Inclusion in this directory is not an endorsement.